SAN DIEGO, Feb. 11 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulltetin Board: SCIE), a San Diego based medical devices company, today announced that it has retained Hayden Communications, a New York based investor relations consulting firm to provide strategic investor relations services.
Jim Hitchin, Chief Executive Officer of SpectraScience, stated, "We have selected Hayden Communications because it has demonstrated expertise and resources that will enable us to more effectively develop and communicate our corporate message to the Street as we transition from an R&D focused business to the commercialization of our WavSTAT(TM) and LUMA(TM) product lines."
Brett Maas, Principal of Hayden Communications, stated "We are looking forward to working with SpectraScience. We are impressed with the company's products as well as the addressable market opportunity and demand for a more effective and less invasive pre-cancer detection offering. In addition, we think that its business model is compelling and believe that the timing is right to begin communicating this message to the investment community."
SpectraScience has filed for 60 patents worldwide on its WavSTAT(TM) Optical Biopsy System and LUMA(TM) cervical cancer imaging system that are used to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT and LUMA systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix, and an application for detection in the throat ("Barrett's esophagus") is being tested.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets spectrophotometry systems
capable of determining whether tissue is normal, pre-cancerous or cancerous
without physically removing tissue from the body. The WavSTAT(TM) Optical
Biopsy System uses light to optically scan tissue and provides the
physician with an immediate analysis. With FDA clearance for sale in the
U.S. and the CE Mark for the European Union, the WavSTAT(TM) system is the
first commercially available product that incorporates this innovative
technology for clinical use. The Company's recently acquired LUMA(TM)
imaging technology has received FDA approval for an optical non-invasive
system that is proven to more effectively detect cervical cancer precursors
than conventional methods available in the market today.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201
|SOURCE SpectraScience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved